Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2006-09-26
2006-09-26
Kishore, Gollamudi S. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C514S824000
Reexamination Certificate
active
07112338
ABSTRACT:
Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.
REFERENCES:
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5110730 (1992-05-01), Edington et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5415869 (1995-05-01), Straubinger et al.
patent: 5512294 (1996-04-01), Li et al.
patent: 5556878 (1996-09-01), Kelly et al.
patent: 5580899 (1996-12-01), Mayhew et al.
patent: 5641755 (1997-06-01), Weichselbaum
patent: 5683715 (1997-11-01), Boni et al.
patent: 5770581 (1998-06-01), Weichselbaum
patent: 5830880 (1998-11-01), Sedlacek et al.
patent: 5837283 (1998-11-01), McDonald et al.
patent: 5837682 (1998-11-01), Folkman
patent: 5885833 (1999-03-01), Mueller et al.
patent: 5935937 (1999-08-01), Smith
patent: 5965739 (1999-10-01), Kelly et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 6096331 (2000-08-01), Desai et al.
patent: 6146659 (2000-11-01), Rahman
patent: 6419692 (2002-07-01), Yang et al.
patent: 0819758 (1998-01-01), None
patent: WO 91/06309 (1991-05-01), None
patent: WO 93/12240 (1993-06-01), None
patent: WO 93/12756 (1993-07-01), None
patent: WO 93/18751 (1993-09-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 93/25673 (1993-12-01), None
patent: WO 95/29242 (1995-11-01), None
patent: WO 00/47235 (2000-08-01), None
Belotti, et al. “The microtubule-affecting drug paclitaxel has antiangiogenic activity”,Clinical Cancer Research, (1996) vol. 2: 1843-1849.
Bernsdorff, et al. “Interaction of the anticancer agent Taxol™ (paclitaxel) with phospholipid bilayers”,J. Biomed. Mater Res.,(1999) vol. 46(2): 141-149.
Brigham, et al. “Expression of a prokaryotic gene in cultured lung endothelial cells after lipofection with a plasmid vector”,Am. J. Respir. Cell Mol. Biol.,(1989) vol. 1: 95-100.
Brigham, et al. “Rapid communication: In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle”, from the Center for Lung Research, Dept. of Med. Path. and Molecular Phys. and Biophys., Vanderbilt U. School of Med., Nashville, Tenn. (1989) pp. 278-284.
Burrows, et al. “Eradication of large solid tumors in mice with an immunotoxin directed aganst tumor vasculature”,Proc. Natl. Acad. Sci. USA, (1993) vol. 90: 8996-9000.
Campbell, et al. “Cationic lipids induce changes in the physical properties of the dipalmitoylphosphatidylcholine bilayers”,Biophys. J.,(1996) vol. 70(2): A416 (WP216).
Campbell, et al. “Cationic liposome mediated drug delivery”,Biophys. J.,(1997) vol. 72(2): A303 (WP313).
Campbell, et al. “Biophysical characterization of cationic lipid-paclitaxel complexes”,AAPS PharmSci.,(1998) p. 1360.
Depre, et al. “Neovascularization in human coronary atherosclerotic lesions”,Cathet. Cardiovasc. Diagn.,(1996) vol. 39(3): 215-220.
Felgner, et al. “Gene therapeutics”,Nature, (1991) vol. 349: 351-352.
Felgner, et al. “Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure”,Proc. Natl. Acad. Sci. USA, (1987) vol. 84: 7413-7417.
Folkman, et al. “Induction of angiogenesis during the transition from hyperplasia to neoplasia”,Nature, (1989) vol. 339: 58-61.
Folkman, et al. “Angiogenic factors”,Science, (1987) vol. 235: 442-447.
Gao, et al. “Cationic liposome-mediated gene transfer”,Gene Therapy, (1995) vol. 2: 710-722.
Hanahan, et al. “Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis”,Cell, (1996) vol. 86: 353-364.
Huang, et al. “Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature”,Science, (1996) vol. 275: 547-550.
Isner. “Cancer and atherosclerosis: The broad mandate of angiogenesis”, Circulation, (1999) vol. 99(13): 1653-1655.
Klauber, et al. “Inhibition of angiogenesis and breast cancer in mice be the microtubule inhibitors 2-methoxyestradiol and Taxol™”,CancerResearch, (1997) vol. 57: 81-86.
LASIC,Liposomes: From Physics to Applications, Elsevier, N.Y. (1996) pp. 265-493.
Liposomes: A practical approach, (1990) R.R.C. New (Ed.), IRL Press at Oxford U. Press, NY.
Morishita, et al. “A novel promoter for vascular endothelial growth factor receptor (fit-1) that confers endothelial-specific gene expression”,J. Biol. Chem.,(1995) 270: 27948-27953.
Moulton, et al. “Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice”,Circulation, (1999) vol. 99(13): 1726-1732.
Teifel, et al. “Optimization of transfection of human endothelial cells”,Endothelium, (1997) vol. 3: 21-35.
Vázquez, et al. “METH-1 a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity”,Journal of Biological Chemistry, (1999) vol. 274(33): 23349-23357.
Xu, et al. “Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity”,Human Gene Therapy, (1997) vol. 8:177-185.
Campbell, et al., “Cationic liposome mediated drug delivery”,Biophys. J.,(1997) vol. 72(2): A303 (WP313).
McLean, et al., “Organ-specific endothelial cell uptake of cationic liposome-DNA complexes in mice”,Amer. J. Physiology, vol. 1, part 2, 273:H387-H404.
Sharma et al. “ Novel Taxol Formulations: Preparation and Characterization of Taxol-Containing Liposomes” Pharmaceutical Research, vol. 11, No. 6, 1994.
McDonald Donald M.
McLean John W.
Thurston O. Gavin
Borden Paula A.
Bozicevic Karl
Bozicevic Field & Francis LLP
Kishore Gollamudi S.
The Regents of the University of California
LandOfFree
Cationic liposome delivery of taxanes to angiogenic blood... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cationic liposome delivery of taxanes to angiogenic blood..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cationic liposome delivery of taxanes to angiogenic blood... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3558968